RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Aiming, Dr. Baudry is a prominent researcher and was apparently a colleague of Dr. Lynch's, but rumors were that they had a falling out a while back. Based on the activities of Lifelike Biomatic, that would make sense.

The AMPA/NMDA receptor combo approach makes sense, although AMPA upregulation by itself already indirectly upregulates NMDA activity, since the NMDA receptor is directly downstream of the AMPA receptor. Some of an AMPA upregulator's activity might in fact already be due to its downstream effect at the NMDA receptor (in Schizophrenia for example). An advantage of stimulating the NMDA receptor via upstream stimulation of the AMPA receptor alone (via an Ampakine) is that the downstream activity should have more allosteric/activity dependent characteristics, compared to a direct NMDA agonist/partial agonist.

The Lifelike approach of stimulating both AMPA and NMDA receptors a little bit independently (at what would be otherwise sub-therapeutic levels), has been shown to have an additive/synergistic effect. Lifelike is apparently trying to patent this sub-threshold concept (sub-therapeutic doses in combination), as well as the fusion approach (combining elements of AMPA and NMDA upregulators into a single compound). However, Lifelike's approach brings into play a whole new set of potential side effects. Theoretically it's a cool idea, but in practice we'll have to see what happens.

The rapidly expanding amount of research activity involving AMPA upmodulation is a sign that Cortex is likely onto something really big, especially with the high impacts. Everyone was extremely skeptical 10 years ago, but now they're all jumping on the bandwagon.